Long-Term Follow-Up Clinical Trial of Subjects Treated with PRAME TCR modified T cells, MDG1011
Latest Information Update: 14 Sep 2023
At a glance
- Drugs MDG 1011 (Primary)
- Indications Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors MediGene AG
Most Recent Events
- 23 Mar 2023 Status changed to completed.
- 25 Oct 2019 New trial record